GLYCOMINE
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options.
GLYCOMINE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.glycomine.com
Total Employee:
1+
Status:
Active
Contact:
(415)617-5755
Email Addresses:
[email protected]
Total Funding:
80 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
AcertaPharma
Acerta Pharma provides drug discovery and development services for oncology and autoimmune diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Mission BioCapital
Mission BioCapital investment in Series B - Glycomine
Sanofi Ventures
Sanofi Ventures investment in Series B - Glycomine
Remiges Ventures
Remiges Ventures investment in Series B - Glycomine
Chiesi Ventures
Chiesi Ventures investment in Series B - Glycomine
RiverVest
RiverVest investment in Series B - Glycomine
Novo Holdings
Novo Holdings investment in Series B - Glycomine
Abingworth
Abingworth investment in Series B - Glycomine
Sanderling Ventures
Sanderling Ventures investment in Series B - Glycomine
Asahi Kasei
Asahi Kasei investment in Series B - Glycomine
Asahi Kasei
Asahi Kasei investment in Series B - Glycomine
Official Site Inspections
http://www.glycomine.com Semrush global rank: 4.76 M Semrush visits lastest month: 1.94 K
- Host name: 155.250.226.35.bc.googleusercontent.com
- IP address: 35.226.250.155
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Glycomine"
Therapeutics For Serious Rare Diseases | About …
Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. There are approximately 7,000 rare disorders worldwide. Each day …See details»
Glycomine - Crunchbase Company Profile & Funding
Organization. Glycomine . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Glycomine is an early-stage biotech working on replacement therapies for rare diseases. ...See details»
Meet The Team - Glycomine
Steven Axon, MSc, MBA CHIEF EXECUTIVE OFFICER READ BIO Hicham Alaoui, Ph.D. Chief Scientific OfficerSee details»
Glycomine Company Profile 2024: Valuation, Funding …
Glycomine General Information Description. Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement therapies such as substrates, enzymes, and proteins …See details»
Glycomine Inc. - LinkedIn
Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease ...See details»
Hicham Alaoui - Chief Scientific Officer at Glycomine - The Org
Chief Scientific Officer at Glycomine. ... Most recently Dr. Alaoui served as Vice President of Biology at Ardelyx where he led a multidisciplinary research organization consisting of …See details»
Glycomine Company Profile - Office Locations, Competitors ... - Craft
Glycomine is a company that develops therapeutics for diseases without treatment options. It focuses on genetic disorders of protein and lipid glycosylation, The company addresses …See details»
Glycomine - Funding, Financials, Valuation & Investors - Crunchbase
Glycomine is an early-stage biotech working on replacement therapies for rare diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... How …See details»
Glycomine Announces First Pediatric Patient Dosed in Phase 2 …
Dec 11, 2023 SAN CARLOS, Calif., December 11, 2023--Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG. …See details»
Events for PMM2-CDG treatments and clinical trials - Glycomine
May 13, 2021 Stay up to date about PMM2-CDG treatments and clinical trialsSee details»
Glycomine, Inc. Announces $33 Million Series B Financing to …
SAN CARLOS, Calif., Aug. 7, 2019 /PRNewswire/ -- Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised …See details»
Glycomine, Inc. Announces $12 Million Series A Financing to …
SAN FRANCISCO, Nov. 16, 2016 /PRNewswire/ -- Glycomine, Inc. a biotechnology company developing a new generation of replacement therapies for rare diseases, today announced …See details»
Glycomine - Abingworth LLP
Glycomine is a clinical-stage biotechnology company developing new therapies for rare genetic diseases. Their lead candidate, GLM101, is a replacement therapy for PMM2-CDG, the most …See details»
Glycomine Appoints Joshua Grass as Chairperson of Board of …
SAN CARLOS, Calif., October 10, 2024 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today …See details»
Glycomine Announces First Dosing in Phase 1 Clinical ... - Business …
Dec 17, 2021 About GLM101, a Potential Treatment for PMM2-CDG (CDG-Ia) Glycomine’s GLM101 is a mannose-1-phosphate replacement therapy in development to treat PMM2-CDG. …See details»
Glycomine Closes $68 Million Series B To Advance Into Clinical …
Jun 23, 2021 New funds raised from new and existing investors to advance clinical testing of GLM101, a novel substrate replacement therapy in development to treat PMM2-CDG SAN …See details»
Glycomine Closes $68 Million Series B to Advance into Clinical …
Jun 23, 2021 Glycomine’s GLM101 is a mannose-1-phosphate replacement therapy in development to treat PMM2-CDG, a disease caused by a deficiency of the enzyme …See details»
GlycoMine | Datasets2Tools
Results: In this study, we present a novel bioinformatics tool called GlycoMine, which is a comprehensive tool for the systematic in silico identification of C-linked, N-linked, and O-linked …See details»
Glycomine Appoints Steven Axon as CEO and Adds Two New …
SAN CARLOS, Calif., July 11, 2022 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced …See details»